Table of Contents

company-logo

Theralase Technologies Inc., a clinical stage pharmaceutical company, engages in the research and development of photo dynamic compounds (PDCs) and their associated drug formulations to treat cancer, bacteria, and viruses in Canada, the United States, and internationally. It also designs, develops, manufactures, and markets patented and proprietary super-pulsed laser technology for the healing of chronic knee pain, as well as for off-label use to heal various nerve, muscle, and joint conditions. In addition, the company develops TLD-1433, which is in Phase II for the treatment of Bacillus Calmette Guérin - Unresponsive Carcinoma In-Situ non-muscle invasive bladder cancer. Further, its product candidates include TLC-2000, a superpulsed and visible red laser technology accelerates healing by reducing pain and inflammation while staying below the Maximal Permissible Exposure limit for tissue, as well as related accessories. Additionally, it provides controller-less cool laser therapy systems comprising TLC-900, TLC-300, and TLC-100. The company has research agreements with the University of Manitoba Medical Microbiology department for the development of a coronavirus vaccine and therapy; and the National Microbiology Laboratory and Public Health Agency of Canada for the research and development of a Canadian-based SARS-CoV-2 vaccine. It sells its products to healthcare practitioners. Theralase Technologies Inc. was founded in 1994 and is based in Toronto, Canada.

Theralase Technologies Dividend Announcement

• Theralase Technologies does not currently offer dividends, we're keeping a close eye on its growth potential and financial developments.
• Stay tuned for updates on Theralase Technologies dividend policy and future announcements. In the meantime, explore other dividend-yielding opportunities on our website.

Theralase Technologies Dividend History

Theralase Technologies Dividend Yield

Theralase Technologies current trailing twelve-month (TTM) dividend yield is -%. Interested in purchasing Theralase Technologies stock? Use our calculator to estimate your expected dividend yield:

Theralase Technologies Financial Ratios

P/E ratio-14.31
PEG ratio-0.51
P/B ratio28.97
ROE-225.69%
Payout ratio0.00%
Current ratio1.91
Quick ratio1.21
Cash Ratio0.38

Theralase Technologies Dividend FAQ

Does Theralase Technologies stock pay dividends?
Theralase Technologies does not currently pay dividends to its shareholders.
Has Theralase Technologies ever paid a dividend?
No, Theralase Technologies has no a history of paying dividends to its shareholders. Theralase Technologies is not known for its dividend payments.
Why doesn't Theralase Technologies pay dividends?
There are several potential reasons why Theralase Technologies would choose not to pay dividends to their shareholders:

1. Growth opportunities: Companies, especially in fast-growing industries like technology, reinvest earnings into expansion, R&D, or acquisitions to fuel future growth and increase company value.

2. Tax implications: Not paying dividends can reduce the tax burden on shareholders, who may prefer to defer taxes until selling shares and realizing capital gains.

3. Investor preferences: Some investors prefer companies to reinvest profits for higher long-term returns, particularly those seeking capital appreciation over income.

4. Capital allocation priorities: Companies may allocate cash to pay down debt, fund share buybacks, or invest in projects with higher returns than dividends.

5. Market expectations: In certain sectors, like technology, reinvesting profits for growth and innovation is often prioritized over distributing dividends to shareholders.
Will Theralase Technologies ever pay a dividend?
The decision for a company to pay dividends depends on various factors including its financial performance, growth prospects, capital allocation priorities, and shareholder preferences. While Theralase Technologies has not paid dividends historically and has instead focused on reinvesting its earnings for growth, it's ultimately up to the company's management and board of directors to decide whether to initiate a dividend policy in the future.
Is Theralase Technologies a dividend aristocrat?
Theralase Technologies is not considered a Dividend Aristocrat. The term "Dividend Aristocrat" is typically used to describe a company in the S&P 500 index that has increased its dividend payouts for at least 25 consecutive years.
Is Theralase Technologies a dividend king?
Theralase Technologies is not classified as a "Dividend King". A Dividend King is a company that has managed to increase its dividend payouts for 50 consecutive years or more, which is an even more selective group than the Dividend Aristocrats.
Is Theralase Technologies a dividend stock?
No, Theralase Technologies is not considered a dividend stock. A dividend stock is a stock of a company that regularly pays out dividends to its shareholders.
How to buy Theralase Technologies stocks?
To buy Theralase Technologies you need a brokerage account. Open an account with a reputable brokerage firm that offers access to the stock market. Consider factors such as fees and account minimums.

Place an order: Use the brokerage's trading platform to place an order to buy Theralase Technologies stock.

Remember that buying stocks involves risk, and it's important to carefully consider your investment goals, risk tolerance, and conduct thorough research before making any investment decisions.